文献速递儿童感染儿童消化与营养

异烟肼与吡嗪酰胺在儿童中的药代动力学:年龄与营养状态的影响

Pharmacokinetic study of isoniazid and pyrazinamide in children: impact of age and nutritional status.
PubMed 文献 · Arch Dis Child · 2018-03-07

该观察性研究纳入40例接受修订版WHO方案每日一线抗结核治疗的结核病患儿,于治疗15天后采集0、2、4、6、8小时血样,测定异烟肼(INH)与吡嗪酰胺(PZA)的Cmax和AUC0-8小时。结果显示修订版WHO剂量对INH在年龄和营养状态方面均足够,而PZA在<3岁和低BMI患儿中药物暴露显著偏低。

要点

  • 修订版WHO剂量下INH暴露在<3岁与>3岁、低BMI与正常BMI间均无显著差异。
  • PZA在<3岁患儿中Cmax和AUC0-8小时均显著低于>3岁患儿。
  • 低BMI患儿PZA的Cmax和AUC0-8小时显著低于正常BMI患儿。

核心结论

  • 修订版WHO剂量对INH而言在年龄和营养状态方面是足够的,但PZA在<3岁和营养不良患儿中药物水平显著偏低。

研究设计与样本

  • 观察性研究,在印度Agra的Sarojini Naidu Medical College和Chennai的National Institute for Research in Tuberculosis开展。
  • 纳入40例确诊结核病并开始按修订版WHO指南每日一线抗结核方案的患儿。
  • 治疗15天后采集0、2、4、6、8小时血样,测定INH和PZA的Cmax与AUC0-8小时。
  • 采用适当统计方法评估年龄和营养状态对药代动力学变量的影响。

主要发现

  • INH在<3岁患儿(Cmax 3.18 µg/mL,AUC0-8小时 15.76 µg/mL hour)与>3岁患儿(Cmax 3.05 µg/mL,AUC0-8小时 14.37 µg/mL hour)间差异不显著(P=0.94,P=0.81)。
  • INH在低BMI患儿(Cmax 3.08 µg/mL,AUC0-8小时 14.81 µg/mL hour)与正常BMI患儿(Cmax 3.09 µg/mL,P=0.99;AUC0-8小时 14.69 µg/mL hour,P=0.82)间相当。
  • PZA在<3岁患儿(Cmax 29.22 µg/mL,AUC0-8小时 155.45 µg/mL hour)显著低于>3岁患儿(Cmax 37.12 µg/mL,P=0.03;AUC 202.63 µg/mL hour,P=0.01)。
  • 低BMI患儿PZA浓度(Cmax 31.90 µg/mL,AUC0-8小时 167.64 µg/mL hour)显著低于正常BMI患儿(Cmax 37.60 µg/mL,P=0.02;AUC0-8小时 208.77 µg/mL hour,P=0.01)。

关键数值与推荐

  • INH在<3岁与>3岁比较:Cmax P=0.94,AUC0-8小时 P=0.81,差异不显著。
  • INH在低BMI与正常BMI比较:Cmax P=0.99,AUC0-8小时 P=0.82,差异不显著。
  • PZA在<3岁与>3岁比较:Cmax P=0.03,AUC0-8小时 P=0.01,差异显著。
  • PZA在低BMI与正常BMI比较:Cmax P=0.02,AUC0-8小时 P=0.01,差异显著。

临床怎么用

  • 按修订版WHO剂量使用INH时,<3岁和营养不良患儿无需因年龄或营养状态调整剂量。
  • 对<3岁和营养不良患儿使用PZA时应关注其药物暴露可能偏低,必要时应考虑治疗药物监测。
  • 临床可依据患儿年龄和营养状态个体化评估PZA给药是否充分。

局限性

  • 原文未报告研究局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate pharmacokinetics of first-line antitubercular drugs, isoniazid (INH) and pyrazinamide (PZA), with revised WHO dosages and to assess its adequacy in relation to age and nutritional status. DESIGN: Observational study. SETTING: This study was conducted at Sarojini Naidu Medical College, Agra, and National Institute for Research in Tuberculosis, Chennai. PATIENTS: 40 subjects diagnosed with tuberculosis were registered in the study and started on daily first-line antitubercular regimen based on the revised WHO guidelines. INTERVENTIONS: Blood samples were collected at 0, 2, 4, 6 and 8 hours from these subjects after 15 days of treatment for drug estimations. MAIN OUTCOME MEASURE: The measurement of drug concentrations (maximum peak concentration (Cmax) and area under the time -concentration curve (AUC0-8 hours)) for INH and PZA. Appropriate statistical methods were used to evaluate the impact of age and nutritional status on pharmacokinetic variables. RESULTS: For INH, the difference in drug exposures in children <3 years (Cmax 3.18 µg/mL and AUC0-8 hours15.76 µg/mL hour) and children >3 years (Cmax3.05 µg/mL and AUC0-8 hours 14.37 µg/mL hour) was not significant (P=0.94, P=0.81, respectively). The drug levels in children with low body mass index (BMI) (Cmax3.08 µg/mL; AUC0-8 hours14.81 µg/mL hour) were also comparable with their normal counterparts (Cmax3.09 µg/mL, P=0.99; AUC0-8 hours 14.69 µg/mL hour, P=0.82). PZA drug exposures obtained in children less than 3 years (Cmax29.22 µg/mL, AUC0-8 hours 155.45 µg/mL hour) were significantly lower compared with drug levels in children above 3 years (Cmax 37.12 µg/mL, P=0.03; AUC 202.63 µg/mL hour, P value=0.01). Children with low BMI had significantly lower drug concentrations (Cmax 31.90 µg/mL, AUC0-8 hours167.64 µg/mL hour) when compared with normal counterparts (Cmax 37.60 µg/mL, P=0.02; AUC0-8 hours 208.77 µg/mL hour, P=0.01). CONCLUSIONS: The revised WHO drug dosages were found to be adequate for INH with respect to age and nutritional status, whereas PZA showed significantly lower drug levels in children <3 years and in malnourished children.

来源:Arch Dis Child,查看原文。版权归原作者所有。

引用

  1. Dayal R, Singh Y, Agarwal D, et al. Pharmacokinetic study of isoniazid and pyrazinamide in children: impact of age and nutritional status. Arch Dis Child. 2018. PMID: 29514812. doi:10.1136/archdischild-2017-313910

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。